Lipella Pharmaceuticals To Publish Abstract Detailing Compelling Preclinical Support For New Product Candidate At ASCO 2024
Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our", "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois. Lipella's abstract, "Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity" will be published at www.asco.org/abstracts.
Dr. Jonathan Kaufman, Chief Executive Officer of Lipella, said, "ASCO's 2024 meeting is the ideal venue for dissemination of our recent progress in the treatment of bladder cancer. Lipella's new product candidate, LP-50 (intravesical pembrolizumab), is intended to be indicated for non-muscle invasive bladder cancer (NMIBC). Our abstract includes preclinical data demonstrating the efficacy of intravesical pembrolizumab in mice, including size-reduction in bladder tumors measured via T2 weighted MRI."
ASCO is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. Its annual meeting is the most significant gathering of oncology professionals worldwide, and aims to change the landscape of cancer care.
Dr. Michael Chancellor, Lipella's Chief Medical Officer, emphasized the significance of this milestone for advancing the company's LP-50 program. He stated, "There exists a critical unmet need for patients with non-muscle invasive bladder cancer. Our proprietary liposomal drug delivery technology enables localized delivery of therapeutics such as pembrolizumab, which can have severe adverse effects when absorbed systemically."
About LP-50
LP-50 is an intravesical formulation of immunoglobulins including local, intravesical PD-1 (i.e. checkpoint) inhibition, intended for the treatment of non-muscle invasive bladder cancer (NMIBC), offering the potential for increasing efficacy while minimizing systemic toxicity.